There are no products listed under this category.
MFNG
MFNG (beta-1,3-N-acetylglucosaminyltransferase manic fringe) is a Golgi glycosyltransferase that elongates O-linked fucose on Notch receptors and so tunes Notch signalling. It is the human homologue of Drosophila manic fringe and belongs to the glycosyltransferase 31 family. Browse Assay Genie's current range of MFNG research reagents below, or read on for the biology behind the target.
MFNG is a glycosyltransferase that initiates the elongation of O-linked fucose residues attached to EGF-like repeats in the extracellular domain of Notch molecules. It has fucose-specific beta-1,3-N-acetylglucosaminyltransferase activity, and this modification alters how Notch responds to its ligands. For NOTCH1, MFNG modifies O-fucose residues at specific EGF-like domains. The result is inhibition of NOTCH1 activation by JAG1 and enhancement of NOTCH1 activation by DLL1, through an increase in binding to DLL1. The enzyme is a membrane protein of the Golgi apparatus, where this glycan processing takes place.
The MFNG gene is a member of the glycosyltransferase 31 gene family, classed by HGNC among the beta 3-glycosyltransferases. The family also includes LFNG and RFNG. These genes encode evolutionarily conserved glycosyltransferases that act in the Notch signalling pathway to define boundaries during embryonic development. Although their genomic structure differs from that of other glycosyltransferases, they share the fucose-specific activity that extends O-linked fucose on Notch. The mouse ortholog is Mfng, which is useful for comparative and developmental work.
The gene was named after Drosophila manic fringe, and earlier HGNC names refer to it as a manic fringe homolog. The protein encoded by this gene may control Notch signalling in claudin-low breast cancer, which links this glycosylation step to cancer biology. Researchers studying the MFNG protein, or using an MFNG antibody or MFNG ELISA kit, are generally interested in how glycan modification of Notch shapes ligand-specific signalling.
MFNG modifies Notch O-fucose, shifting NOTCH1 responses toward DLL1 activation and away from JAG1 activation.
MFNG extends O-linked fucose on EGF-like repeats, making it a model for studying glycosyltransferase control of receptor function.
Fringe family glycosyltransferases act in Notch signalling to define boundaries during embryonic development.
MFNG may control Notch signalling in claudin-low breast cancer, pointing to a role in tumour signalling studies.
MFNG is a Golgi glycosyltransferase that starts the elongation of O-linked fucose on EGF-like repeats of Notch. This modification inhibits NOTCH1 activation by JAG1 and enhances activation by DLL1, partly by increasing NOTCH1 binding to DLL1.
The full HGNC name is MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, and the UniProt name is beta-1,3-N-acetylglucosaminyltransferase manic fringe. Earlier names were manic fringe (Drosophila) homolog. No alternative gene symbols are recorded.
MFNG, LFNG and RFNG belong to the glycosyltransferase 31 family. All three encode conserved enzymes with fucose-specific beta-1,3-N-acetylglucosaminyltransferase activity that elongates O-linked fucose on Notch. Mouse has an Mfng ortholog; check the datasheet of any product for its validated reactivity.
Fringe family glycosyltransferases, Notch receptors and Notch ligands that act alongside MFNG in the Notch signalling pathway.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O00587; product specifications from Assay Genie datasheets.
There are no products listed under this category.